EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

INNOSTAR ORD A (SHH) EQSW Exp: (688710) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of INNOSTAR ORD A (SHH) EQSW Exp: ¥10.42, price ¥105, upside -90.1%, quality 27 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN

IO Some data Sep 24, 2026

INNOSTAR ORD A (SHH) EQSW Exp:

688710 · SHG

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥10.42 · Strongly overvalued (−90%)
!Quality 27/100
!Weak Growth (revenue 3y −2.0 %/yr)
!Loss-making · -2.9% net margin (TTM)
!negative free cash flow
!Trails peers (2/10)
!Narrow moat 26/100
!Evidence only medium, so the estimate is less certain
!Weak on future: 2 out of 100
!Weak on dividend: 7 out of 100
Watch INNOSTAR ORD A (SHH) EQSW Exp: for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥104.77 ¥22.76 Fair Value ¥10.42 Sep 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

25‑month range ¥22.76 – ¥104.77 · fair‑value band ¥10.25 – ¥10.57 · the ¥104.77 price screens above the ¥10.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines.

Show more

Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines. The company was founded in 2010 and is based in Shanghai, China.

Stock analysis

INNOSTAR ORD A (SHH) EQSW Exp: (688710) currently trades at ¥104.77, while our model-based Fair Value estimate is ¥10.42, implying the stock looks roughly 905.0% overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥13.02 per share, and 0 of the 8 models we run sit above the ¥104.77 price.

Bear case: the Dividend Discount group reads lowest at ¥4.03, and 8 of the 8 models stay below the price. Evidence for this calculation is medium.

Scenario range: ¥10.25 (bear) to ¥10.57 (bull), the price of ¥104.77 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

INNOSTAR ORD A (SHH) EQSW Exp: reported revenue of 811M CNY in FY2025 versus 582M CNY in FY2021, a compound +8.7%/yr. Reported net income was −30.5M CNY in FY2025.

Key figures

Market cap 14.8B CNY (≈ $2.2B) · P/S ratio 16.1 · EPS (TTM) ¥−0.1700 · Dividend yield 0.3% · Net margin −3.8% · Return on equity 0.0% · Return on assets (EBIT) 5.5% · Operating margin 10.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 157% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −90%, 688710 screens richer than that median.

Fair Value models

Bear ¥10.25 Fair Value ¥10.42 Bull ¥10.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV ¥10.35 ¥10.55 ¥10.73 68
ROIC Compounder ¥10.35 ¥10.55 ¥10.73 67
Gordon GGM ¥2.94 ¥4.03 ¥5.14 66
All 8 models by family
Earnings-Based
EPV ¥10.35 ¥10.55 ¥10.73 68
Dividend Discount
Gordon GGM ¥2.94 ¥4.03 ¥5.14 66
DDM Multi-Stage ¥2.94 ¥4.08 ¥5.42 64
Multiples
EV/EBIT ¥12.05 ¥13.02 ¥14.00 63
EV/EBITDA ¥19.89 ¥23.47 ¥27.06 64
EV/Revenue ¥10.61 ¥11.24 ¥11.87 52
Asset-Based
NCAV (Graham) ¥8.24 ¥11.04 ¥16.48 51
Economic Profit
ROIC Compounder ¥10.35 ¥10.55 ¥10.73 67

Open the full fair value analysis →

Notify me when 688710 reaches fair value

Put 688710 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 27/100

Of which business quality 31 · Market factors (momentum, volatility) 70

Profitability 10
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 18
Earnings quality: real cash, not paper profit
Fin. Strength 83
Balance sheet, leverage, solvency risk
Investment 30
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−28.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
18.7% (2021) → 2.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688710 screens 905% overvalued. Compare with Eli Lilly and Company →

Compare INNOSTAR ORD A (SHH) EQSW Exp: with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 71 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Profitability
Return on assets −1% · Bottom 25%
Net margin (TTM) −3% · Bottom 25%
Operating margin (TTM) 11% · Below median
Growth and dividend
Revenue growth 0% · Below median
Dividend yield (TTM) 0.3% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/B 0.95× · Cheapest 25%
P/S (TTM) 2.72× · Cheaper than median
EV/EBITDA 29.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)2 · sector 29
PAST (return on equity)0 · sector 52
HEALTH (low debt)0 · sector 92
DIVIDEND (yield)7 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Eli Lilly and Company LLY $1,170 $791.40 −32%
Johnson & Johnson, JNJ $269.19 $169.04 −37%
AbbVie Inc ABBV $265.21 $259.66 −2%
Roche Holding RO CHF 375.20 CHF 329.11 −12%
Merck & Co MRK $150.91 $129.12 −14%
Novartis AG NOVN CHF 116.46 CHF 119.10 +2%
Amgen Inc AMGN $410.24 $451.26 +10%
Gilead Sciences, Inc GILD $152.67 $198.51 +30%
Pfizer Inc PFE $27.93 $24.87 −11%
Bristol-Myers Squibb Company BMY $62.25 $75.98 +22%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

INNOSTAR ORD A (SHH) EQSW Exp: · Fair Value
¥10.42 −905%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "INNOSTAR ORD A (SHH) EQSW Exp: Fair Value". https://www.fairvalue-calculator.com/stock/688710

Frequently asked questions

Is INNOSTAR ORD A (SHH) EQSW Exp: (688710) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥10.42 versus a price of ¥104.77, about −90% upside (overvalued).
What is the fair value of 688710?
Our model-based fair value for INNOSTAR ORD A (SHH) EQSW Exp: is ¥10.42 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥104.77.
What is the quality score of 688710?
INNOSTAR ORD A (SHH) EQSW Exp: has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Our model-based price target is the fair value of ¥10.42 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario ¥10.25, optimistic scenario ¥10.57. It is a calculation from audited fundamentals, not an analyst target.
What is the INNOSTAR ORD A (SHH) EQSW Exp: stock forecast for 2026?
Our models put fair value at ¥10.42, about −90% upside versus a price of ¥104.77 (overvalued). Cautious scenario ¥10.25, optimistic scenario ¥10.57. The calculation is refreshed regularly with new filings.
What is the revenue of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
INNOSTAR ORD A (SHH) EQSW Exp: reported trailing-twelve-month revenue of about 812M CNY (latest available figure, as of Sep 24, 2026).
Does INNOSTAR ORD A (SHH) EQSW Exp: pay a dividend?
INNOSTAR ORD A (SHH) EQSW Exp: currently shows a dividend yield of about 0.35% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For INNOSTAR ORD A (SHH) EQSW Exp: it is ¥10.42 per share (as of Sep 24, 2026), against a price of ¥104.77. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is INNOSTAR ORD A (SHH) EQSW Exp: stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688710 trades above its calculated fair value: price ¥104.77, fair value ¥10.42, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688710?
No. The price is what the market pays today (¥104.77); the fair value is what the company's own numbers justify (¥10.42). For INNOSTAR ORD A (SHH) EQSW Exp: the two are ¥94.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is INNOSTAR ORD A (SHH) EQSW Exp: worth?
The market values INNOSTAR ORD A (SHH) EQSW Exp: at about 14.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥104.77; our models calculate a fair value of ¥10.42 per share.
What do the bullish and bearish scenarios say about 688710?
Our models span a range for INNOSTAR ORD A (SHH) EQSW Exp:: cautious scenario ¥10.25, base ¥10.42, optimistic ¥10.57 per share (as of Sep 24, 2026, price ¥104.77). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Balance-sheet figures for INNOSTAR ORD A (SHH) EQSW Exp: (as of Sep 24, 2026): return on equity 0.0%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 688710 from its 52-week high?
INNOSTAR ORD A (SHH) EQSW Exp: trades at ¥104.77, at its 52-week high of ¥104.77 and 157% above the low of ¥40.81 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.42 is for.
Which stocks are comparable to INNOSTAR ORD A (SHH) EQSW Exp:?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is INNOSTAR ORD A (SHH) EQSW Exp: stock attractive at the current price?
The data as of Sep 24, 2026: price ¥104.77, calculated fair value ¥10.42 (−90%), Quality Score 27/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688710 calculated?
We run INNOSTAR ORD A (SHH) EQSW Exp: through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥10.42, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. INNOSTAR ORD A (SHH) EQSW Exp: itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The closing price on Sep 23, 2026 was ¥104.77. Our model-based fair value is ¥10.42, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with INNOSTAR ORD A (SHH) EQSW Exp: right now?
The price sits above even our optimistic bull case (¥10.57). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (¥10.25 to ¥10.57), unusually little disagreement for a valuation.

Key figures of INNOSTAR ORD A (SHH) EQSW Exp:

How large is the market capitalisation of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The market capitalisation of INNOSTAR ORD A (SHH) EQSW Exp: is 14.8B CNY (≈ $2.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The price-to-sales ratio of INNOSTAR ORD A (SHH) EQSW Exp: is 16.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Earnings per share at INNOSTAR ORD A (SHH) EQSW Exp: are ¥−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The dividend yield of INNOSTAR ORD A (SHH) EQSW Exp: is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The net margin of INNOSTAR ORD A (SHH) EQSW Exp: is −3.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The return on equity (ROE) of INNOSTAR ORD A (SHH) EQSW Exp: is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
On an EBIT basis the return on assets of INNOSTAR ORD A (SHH) EQSW Exp: is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
The operating margin of INNOSTAR ORD A (SHH) EQSW Exp: is 10.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Revenue at INNOSTAR ORD A (SHH) EQSW Exp: is growing +0.4% versus a year earlier (3y avg −2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at INNOSTAR ORD A (SHH) EQSW Exp: (688710)?
Earnings per share at INNOSTAR ORD A (SHH) EQSW Exp: are growing +125% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does INNOSTAR ORD A (SHH) EQSW Exp: (688710) generate?
The free cash flow of INNOSTAR ORD A (SHH) EQSW Exp: is −32.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch INNOSTAR ORD A (SHH) EQSW Exp: in the live analysis

One click puts INNOSTAR ORD A (SHH) EQSW Exp: on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.